Toggle navigation
    * About
    * Portfolio
    * Initiatives
        + Strategic Partnerships
    * Team
    * News
    * Contact

        Our Portfolio

        We build disruptive companies.
        Meet them.

        Read what our entrepeneurs are saying about ARCH.

                    “What defines ARCH is the willingness to think big – to go for bold transformative ideas rather than settle for incremental progress.

                    ARCH is unique in its ability to see the waves before they start to form.

                    They were the initial glue that brought our scientific founders and investors together to form Agios. ARCH bet on new biology, put the right people, talent, and money together, and was interested in building for the long-term, not a quick flip. ARCH’s network and insight into the markets played an instrumental role in us having one of the most successful IPOs in 2013. When you think 1X, ARCH will push you to think 10X.”

                    — David Schenkein, MD, Former CEO

                      Location: Cambridge, MA Date of Founding:
                      Arch Partners:
            Read More

                    “There is no other venture firm like ARCH. They are truly unique when it comes to taking real risk to tackle big challenges.

                    Their desire to take on large medical problems, regardless of past failures, knowing that we can succeed in these areas and make an enormous difference, is unprecedented. They are looking to work with groundbreaking scientists to make large leaps forward in scientific insight and therapeutic discovery. ARCH wasn’t interested in simply seeding our company and walking away, they are deeply passionate about the disease areas that we are working on solving, and have a personal interest in seeing us succeed for patients.”

                    — Ryan Watts, Ph.D., CEO

                      Location: San Francisco, CA Date of Founding:
                      Arch Partners:
            Read More

                    “I’ve worked with ARCH for more than a decade, from Illumina, to GRAIL, and Receptos. ARCH’s bold and creative thinking helped launch each of these companies. ARCH brought together talented teams, groundbreaking science and technology, and the right amount of funding needed to pursue big missions. They served as strategic thought partners, always focused on the longer-term vision, while also meeting both short-term business goals.

                    I consider ARCH’s advice, expertise, and network to be invaluable to scientific entrepreneurs looking to change the world of medicine.”

                    — Bill Rastetter, Ph.D., Former Chairman

                      Location: Menlo Park, CA Date of Founding: Sample Date
                      Arch Partners:
            Read More

                    “I’ve had the pleasure to work with ARCH many times, including at Illumina, where they were a founding investor.

                    In my own relationship with ARCH, I continually marvel at their deep involvement and commitment to help a CEO achieve the objectives of the company.

                    ARCH brings a deep understanding of markets and technology that is invaluable as companies develop and consider strategic options and business models, and are extraordinarily helpful in connecting them to important industry partners, academic experts, and other investors. They are unique in being able to recognize the transformative potential of very early and unproven technologies, and then committing substantial amounts of time and capital to bring those technologies to market.”

                    — Jay Flatley, former Executive Chairman

                      Location: Santa Clara, CA Date of Founding: Sample Date
                      Arch Partners:
            Read More

                    “ARCH isn’t interested in a quick win. They’re committed to building truly transformational companies, and understand that takes more than a one-time investment.

                    ARCH is adept at finding new scientific opportunities that have the potential to make a big impact on people’s lives and bringing the right people and resources to realize that potential. ARCH has been a true and valued partner to our management team, helping us tackle complex challenges by pushing us to think creatively and boldly.”

                    — Hans Bishop, Former CEO

                      Location: Seattle, WA Date of Founding:
                      Arch Partners:
            Read More

                    “ARCH has been much more of a partner than an investor.

                    ARCH has grown with us—facilitating introductions through their amazing network, supported by long-term relationships. In our early days, they provided introductions to key advisors to foster strategic partnerships and investments. As we have grown, ARCH has helped us network with leaders across all business segments—from investors to customers and potential employees. More than anything, ARCH embodies the phrase “value-add,” as they have provided so much more than investment capital.”

                    — Emily LeProust, Ph.D., CEO

                      Location: San Francisco, CA Date of Founding: Sample Date
                      Arch Partners:
            Read More

                    “ARCH has a big vision, audacious goals, great connections, amazing fundraising skills, and thoughtful advice.

                    More than other firms, ARCH knows how to identify an opportunity, fund them generously, attract high-quality teams, and build successful and dynamic companies.

                    Vir Biotechnology would not exist without ARCH finding the science and painting the vision that attracted our management team, which is now helping make the vision a reality. Today, ARCH continues to support the company, helping with strategic moves and introducing new ideas and partners.”

                    — George Scangos, Ph.D., Former CEO

                      Location: San Francisco, CA Date of Founding: Sample Date
                      Arch Partners:
            Read More

                    “What defines ARCH is the willingness to think big – to go for bold transformative ideas rather than settle for incremental progress.

                    ARCH is unique in its ability to see the waves before they start to form.

                    They were the initial glue that brought our scientific founders and investors together to form Agios. ARCH bet on new biology, put the right people, talent, and money together, and was interested in building for the long-term, not a quick flip. ARCH’s network and insight into the markets played an instrumental role in us having one of the most successful IPOs in 2013. When you think 1X, ARCH will push you to think 10X.”

                    — David Schenkein, MD, Former CEO

                      Location: Cambridge, MA Date of Founding:
                      Arch Partners:

                    “There is no other venture firm like ARCH. They are truly unique when it comes to taking real risk to tackle big challenges.

                    Their desire to take on large medical problems, regardless of past failures, knowing that we can succeed in these areas and make an enormous difference, is unprecedented. They are looking to work with groundbreaking scientists to make large leaps forward in scientific insight and therapeutic discovery. ARCH wasn’t interested in simply seeding our company and walking away, they are deeply passionate about the disease areas that we are working on solving, and have a personal interest in seeing us succeed for patients.”

                    — Ryan Watts, Ph.D., CEO

                      Location: San Francisco, CA Date of Founding:
                      Arch Partners:

                    “I’ve worked with ARCH for more than a decade, from Illumina, to GRAIL, and Receptos. ARCH’s bold and creative thinking helped launch each of these companies. ARCH brought together talented teams, groundbreaking science and technology, and the right amount of funding needed to pursue big missions. They served as strategic thought partners, always focused on the longer-term vision, while also meeting both short-term business goals.

                    I consider ARCH’s advice, expertise, and network to be invaluable to scientific entrepreneurs looking to change the world of medicine.”

                    — Bill Rastetter, Ph.D., Former Chairman

                      Location: Menlo Park, CA Date of Founding: Sample Date
                      Arch Partners:

                    “I’ve had the pleasure to work with ARCH many times, including at Illumina, where they were a founding investor.

                    In my own relationship with ARCH, I continually marvel at their deep involvement and commitment to help a CEO achieve the objectives of the company.

                    ARCH brings a deep understanding of markets and technology that is invaluable as companies develop and consider strategic options and business models, and are extraordinarily helpful in connecting them to important industry partners, academic experts, and other investors. They are unique in being able to recognize the transformative potential of very early and unproven technologies, and then committing substantial amounts of time and capital to bring those technologies to market.”

                    — Jay Flatley, former Executive Chairman

                      Location: Santa Clara, CA Date of Founding: Sample Date
                      Arch Partners:

                    “ARCH isn’t interested in a quick win. They’re committed to building truly transformational companies, and understand that takes more than a one-time investment.

                    ARCH is adept at finding new scientific opportunities that have the potential to make a big impact on people’s lives and bringing the right people and resources to realize that potential. ARCH has been a true and valued partner to our management team, helping us tackle complex challenges by pushing us to think creatively and boldly.”

                    — Hans Bishop, Former CEO

                      Location: Seattle, WA Date of Founding:
                      Arch Partners:

                    “ARCH has been much more of a partner than an investor.

                    ARCH has grown with us—facilitating introductions through their amazing network, supported by long-term relationships. In our early days, they provided introductions to key advisors to foster strategic partnerships and investments. As we have grown, ARCH has helped us network with leaders across all business segments—from investors to customers and potential employees. More than anything, ARCH embodies the phrase “value-add,” as they have provided so much more than investment capital.”

                    — Emily LeProust, Ph.D., CEO

                      Location: San Francisco, CA Date of Founding: Sample Date
                      Arch Partners:

                    “ARCH has a big vision, audacious goals, great connections, amazing fundraising skills, and thoughtful advice.

                    More than other firms, ARCH knows how to identify an opportunity, fund them generously, attract high-quality teams, and build successful and dynamic companies.

                    Vir Biotechnology would not exist without ARCH finding the science and painting the vision that attracted our management team, which is now helping make the vision a reality. Today, ARCH continues to support the company, helping with strategic moves and introducing new ideas and partners.”

                    — George Scangos, Ph.D., Former CEO

                      Location: San Francisco, CA Date of Founding: Sample Date
                      Arch Partners:

        Disruptive Companies from Great Science

        ARCH Portfolio Companies

              908 Devices
                Point-of-need chemical and biomolecular analysis devices
                Boston, MA | NASDAQ: MASS
              Accompany Health
                Correcting disparities in home health care for marginalized communities.
                Bethesda, MD
              Aera Therapeutics
                Protein nanoparticle delivery platform to deliver genetic payloads into multiple organs for better response and fewer reactions.
                Cambridge, MA
              Agios Pharmaceuticals
                Gene-targeted cancer therapeutics
                Cambridge, MA | NASDAQ: AGIO
              AIRNA
                RNA editing technology harnessing endogenous enzymes to prevent off-target edits.
              Akamis Bio
                Systemic immune oncology therapies
                Abingdon, UK
              Aledade
                Accountable care organizations
                Bethesda, MD
              Alnylam Pharmaceuticals
                RNAi therapeutics
                Cambridge, MA | NASDAQ: ALNY
              Altos Labs
                Cellular resilience and rejuvenation
                San Diego, CA
              Arbor Biotechnologies
                Protein Discovery Platform for Therapeutics
                Cambridge, MA
              Areteia Therapeutics
                The first oral drug to treat eosinophilic asthma.
                CHAPEL HILL, NC
              Arsenal Biosciences
                Programmable cell cancer therapies
                South San Francisco, CA
              Aspen Neuroscience
                Regenerative medicine focused on Parkinson’s Disease
                San Diego, CA
              Autobahn Therapeutics
                Thyromimetics drug discovery
                San Diego, CA
              Basking Biosciences
                Reversible thrombolytic therapy for acute ischemic stroke
                Columbus, OH
              BE Biopharma
                New class of engineered B cell medicines.
                Cambridge, MA
              Beam Therapeutics
                CRISPR base-editing platform
                Cambridge, MA | NASDAQ: BEAM
              Bit Bio
                Precise reprogramming of stem cells into any desired cell type
                Cambridge, UK
              Bitterroot Bio
                Cardiovascular disease therapies
                Palo Alto, CA
              Boundless Bio
                Therapeutics based on ecDNA discoveries
                San Diego, CA | NASDAQ: BOLD
              Brii Biosciences
                Transforming China's public health
                Shanghai, China & San Francisco, CA | HKEX: 2137
              Carrick Therapeutics
                Cancer therapeutics
                Boston, MA
              City Therapeutics
                Next generation siRNA medicines
                Cambridge, MA
              CStone Pharmaceuticals
                China-based cancer therapeutics
                Suzhou, China | HKEX: 2616
              Curie Bio
                Helping biotech company founders launch successful therapeutics firms
                Boston, MA
              Cytrellis Biosystems
                Aesthetic medicine
                Woburn, MA
              Denali Therapeutics
                Neurodegenerative therapeutics
                San Francisco, CA | NASDAQ: DNLI
              Dewpoint Therapeutics
                Translating biomolecular condensate into therapeutics
                Boston, MA
              Dispatch Biotherapeutics
                Immunotherapies to reimagine cancer therapy
                Philadelphia, PA
              eGenesis
                Gene-editing for organ transplantation
                Cambridge, MA
              Elephas Biosciences
                Cancer diagnostics to accurately predict clinical outcomes and accelerate drug development
                Madison, WI
              Encoded Therapeutics
                Precision gene therapies
                South San Francisco, CA
              Encodia
                Protein Analysis Platform
                San Diego, CA
              Enumerix
                Precision DNA counting platform
                Palo Alto, CA
              EQRx (Acquired)
                Re-engineering drug development and pricing models
                Cambridge, MA | NASDAQ: EQRX
              Erasca
                Erasing cancer with AI drug discovery platform
                San Diego, CA | NASDAQ: ERAS
              Faraday Pharmaceuticals
                Ischemic trauma therapies
                Seattle, WA
              Gate Bioscience
                Small molecule drugs against disease-causing proteins
                Brisbane, CA
              Generate Biomedicines
                Multi-disciplinary platform for developing protein therapeutics
                Cambridge, MA
              Gossamer Bio
                Therapeutics in immunology, inflammation, and oncology
                San Diego, CA | NASDAQ: GOSS
              Grail (Acquired)
                Detect cancer early, when it can be cured.
                Menlo Park, CA
              hC Bioscience
                tRNA-based therapeutics for cancer and rare disease
                Boston, MA
              HiberCell
                Therapeutics to prevent cancer relapse and metastasis
                New York, NY
              Homeward Health
                Delivering healthcare to rural communities using a hybrid model of virtual and in-person services
                San Francisco, CA
              Hua Medicine
                Asia-based pharmaceutical development
                Shanghai, China | HKEX: 2552
              Human Immunology Biosciences (Acquired)
                Precision immunology therapies
                San Francisco, CA
              Illumina
                Diagnostics screening platform
                Santa Clara, CA | NASDAQ: ILMN
              Inograft Biotherapeutics
                Organ and stem cell transplant immune suppression therapies
                Palo Alto, CA
              Insitro
                Machine learning for drug discovery
                South San Francisco, CA
              Jaguar Gene Therapy
                Gene therapies for severe genetic diseases
                Lake Forest, IL
              Juno Therapeutics (Acquired)
                Cancer immunotherapies
                Seattle, WA | NASDAQ: JUNO
              JUST Biotherapeutics (Acquired)
                Therapeutics development & manufacturing
                Seattle, WA
              JW Therapeutics
                China-based cancer therapeutics
                Shanghai, China | HKEX: 2126
              Kardigan
                Curative therapies for cardiovascular disease
                South San Francisco, CA
              Karuna Therapeutics (Acquired)
                Therapeutics for cognitive impairment
                Boston, MA | NASDAQ: KRTX
              Kisbee Therapeutics
                Neurodegenerative disease therapies based on lipid biology
                Watertown, MA
              KSQ Therapeutics
                Matching Genomic Function to Diseases
                Cambridge, MA
              Kura Oncology
                Cancer therapeutics
                San Diego, CA | NASDAQ: KURA
              Kythera Biopharmaceuticals (Acquired)
                Aesthetic medicine
                Parsippany, NJ & CA | NASDAQ: KYTH
              LifeMine Therapeutics
                Biosynthetic therapeutics
                Cambridge, MA
              Lifordi Immunotherapeutics
                Leveraging anti-drug conjugates to develop treatments for autoimmune and inflammatory disorders
                Boston, MA
              Lightcast Discovery
                Microfluidic platform for complex and single cell analysis
                Cambridge, UK
              Lilac Therapeutics
                Small molecule therapies to treat kidney stones
                Richmond, CA
              Lyell Immunopharma
                Curative cell-based immunotherapeutics for cancer
                San Francisco, CA & Seattle, WA | NASDAQ: LYEL
              Magnet Biomedicine
                Discovery platform for molecular glues that exhibit therapeutic activity
                Cambridge, MA
              Matter Neuroscience
                App pairing personal experience and neuroscience to build better lives
              Maze Therapeutics
                Targeting genetic modifiers that can protect against disease
                San Francisco, CA | NASDAQ: MAZE
              Metsera
                Metabolic disease therapeutics
                Boston, MA | NASDAQ: MTSR
              Mirador Therapeutics
                Precision medicines for immunology and inflammation
                San Diego, CA
              Moleculent AB
                Cell-cell communication profiling platform
                Stockholm, Sweden
              Moonwalk Biosciences
                Precision epigenetic editing
                SOUTH SAN FRANCISCO, CA
              Mozart Therapeutics
                Autoimmune disease therapeutics
                Seattle, WA
              Myeloid Therapeutics
                Novel mRNA-immunotherapies to treat cancer
                Cambridge, MA
              National Resilience
                Re-engineering drug manufacturing in the U.S. and abroad
                La Jolla, CA
              nChroma Bio
                In vivo delivery methods for genetic medicines
                Cambridge, MA
              Neumora Therapeutics
                Precision medicines for brain diseases and disorders.
                Watertown, MA | NASDAQ: NMRA
              Nutcracker Therapeutics
                RNA immunotherapies manufacturing platform
                Emeryville, CA
              Omniome (Acquired)
                SBB DNA sequencing platform
                San Diego, CA
              OneBioMed
                Instruments for nucleic acid purification/isolation
                Singapore, SG
              ONI
                Desktop super-resolution microscopy
                Oxford, UK
              Orbital Therapeutics
                Platform at the intersection of RNA technology, delivery methods, data science and automation
                Cambridge, MA
              Parabilis Medicines
                New class of drugs aimed at achieving universal druggability for even the most difficult targets
                Cambridge, MA
              Paradigm Health
                Reimagining the clinical trial ecosystem to provide equitable access for all patients
                New York, NY
              Paratus Sciences
                Platform to study bat biology and genomics
                New York, NY
              Pheast Therapeutics
                Immuno-oncology therapies for difficult-to-treat and resistant cancers
                Palo Alto, CA
              Pretzel Therapeutics
                Therapeutics for mitochondrial diseases
                Waltham, MA
              Prime Medicine
                Advanced CRISPR gene editing technology
                Cambridge, MA | NASDAQ: PRME
              Protillion Biosciences
                Rapid platform for antibody discovery and optimization
                Burlingame, CA
              Qihan Biotech
                Next generation cells and organs that can evade immune attacks
                Hangzhou, China
              Quanterix
                Digital diagnostics for molecular detection
                Lexington, MA | NASDAQ: QTRX
              Quantum Circuits
                Developing the first practical quantum computers
                New Haven, CT
              Rapport Therapeutics
                Precision medicines for neurological disorders.
                Boston, MA | NASDAQ: RAPP
              Reactive Biosciences
                Medicines harnessing the unique properties of boron
                Durham, NC
              Receptos (Acquired)
                Targeted drug discovery platform
                Summit, NJ & CA | NASDAQ: RCPT
              Recuro Health
                Digital health platform
                Dallas, TX
              Remix Therapeutics
                Therapeutics to reprogram RNA processing
                Watertown, MA
              RhyGaze AG
                Cone optogenetics for vision restoration
                Basel, Switzerland
              RIPPL Care
                Mental healthcare for seniors with dementia and neurocognitive conditions
                Seattle, WA
              ROME Therapeutics
                Harnessing the power of the repeatome to develop a new class of therapies for cancer and autoimmune diseases
                Cambridge, MA
              Sana Biotechnology
                Creating and delivering engineered cells as medicine
                Seattle, WA | NASDAQ: SANA
              Scale Biosciences
                Single-cell sequencing and analysis for research and clinical applications
                San Diego, CA
              Scholar Rock
                Niche activator therapeutics
                Cambridge, MA | NASDAQ: SRRK
              SciNeuro Pharmaceuticals
                Neurotherapeutics to improve China-based patient care
                Shanghai, China
              Seaport Therapeutics
                Neuropsychiatric medicines
                Seaport Boston, MA
              Semma Therapeutics (Acquired)
                Diabetes therapeutics
                Cambridge, MA
              Singleron Biotechnologies
                Massive single-cell processing equipment, software ancd libraries
                Nanjing, China
              Singular Genomics Systems
                Genomic analysis instrumentation
                San Diego, CA | NASDAQ: OMIC
              Sironax
                Therapeutics for inflammatory and nero degenerative diseases
                Beijing, China
              Skylark Bio
                Breakthrough gene therapies to treat hearing loss and sensory impairments
                Cambridge, MA
              Slingshot Biosciences
                On-demand synthetic cell platform
                Emeryville, CA
              Sonoma Biotherapeutics
                T cell therapies for autoimmune and degenerative diseases
                San Francisco, CA / Seattle, WA
              SonoThera
                Ultrasound-directed non-viral gene delivery approach
                South San Francisco, CA
              SunBird Bio
                Blood-based diagnostics for the detection of neurodegenerative diseases
                Singapore
              Synchron
                Brain-computer interface system to restore motor and communication capabilities for paralyzed patients
                Brooklyn, NY
              Tenvie
                Therapeutics for inflammation, metabolic dysfunction and lysosomal function
                South San Francisco, CA
              Transcenta Holding
                Fully integrated antibody-based biotherapeutics company
                Suzhou, China & Boston, MA | HKEX: 6628
              Treeline Biosciences
                Difficult-to-drug molecular targets in oncology
                Stamford, CT
              Trotana Therapeutics
                Medicines targeting RNA binding proteins
                San Diego, CA
              Twist Bioscience
                Synthetic DNA manufacturing
                San Francisco, CA | NASDAQ: TWST
              Unity Biotechnology
                Therapeutics for age-related diseases & conditions
                San Francisco, CA | NASDAQ: UBX
              VBI Vaccines
                Vaccine therapeutics
                Cambridge, MA & Quebec, Canada | NASDAQ: VBIV
              Verve Therapeutics
                Gene editing therapies to permanently reduce cardiovascular disease
                Cambridge, MA | NASDAQ: VERV
              Vesalius Therapeutics
                AI/ML drug discovery platform for common illnesses
                Cambridge, MA
              Vilya
                Synthetic protein science platform for artificial molecule design
                Seattle, WA
              Vir Biotechnology
                Perpetual vaccine platform
                San Francisco, CA | NASDAQ: VIR
              Vividion Therapeutics (Acquired)
                Protein-based therapeutics
                San Francisco, CA
              Vizgen
                Gene profiling instrumentation and data analysis
                Cambridge, MA
              Volastra Therapeutics
                Cancer genomics and precision medicines
                New York, NY
              Walden Biosciences
                Precision renal therapeutics
                Cambridge, MA
              Xaira Therapeutics
                AI for drug discovery
                San Francisco, CA
        Download a list of ARCH’s historical investments
      COMPANY
        * About
        * Portfolio
        * Initiatives
            + Strategic Partnerships
        * Team
        * News
        * Contact
      LOCATIONS
        * Chicago, IL
        * Seattle, WA
      ©2025 Arch Venture Partners

      Terms of Use
      Privacy Policy

      CONNECT